Recently, Mazzaferro and colleagues developed a new model based on the AFP level, size, and number of nodules able to estimate at any time (pre- or post-downstaging) the probability of 5-year post-LT HCC recurrence-free survival—the Metroticket 2.0 Model (11). The gene discussed is AFP; the disease is hepatocellular carcinoma.